<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article article-type="research-article">
  <?properties open_access?>
  <!-- Original-type: ra-->
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id>
      <journal-title>British Journal of Cancer</journal-title>
      <issn pub-type="ppub">0007-0920</issn>
      <issn pub-type="epub">1532-1827</issn>
      <publisher>
        <publisher-name>Nature Publishing Group</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">11487260</article-id>
      <article-id pub-id-type="pmc">2364073</article-id>
      <article-id pub-id-type="pii">6691900</article-id>
      <article-id pub-id-type="doi">10.1054/bjoc.2001.1900</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Regular Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Longstanding survival without cancer progression in a patient affected by endometrial carcinoma treated primarily with leuprolide</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Noci</surname>
            <given-names>I</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Borri</surname>
            <given-names>P</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bonfirraro</surname>
            <given-names>G</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chieffi</surname>
            <given-names>O</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Arcangeli</surname>
            <given-names>A</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cherubini</surname>
            <given-names>A</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dabizzi</surname>
            <given-names>S</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Buccoliero</surname>
            <given-names>A M</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Paglierani</surname>
            <given-names>M</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Taddei</surname>
            <given-names>G L</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">3</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label>Department of Gynaecology, Perinatal Medicine and Human Reproduction, University of Florence, viale G. B. Morgagni 85, 50134, Firenze</aff>
      <aff id="aff2"><label>2</label>Department of Experimental Pathology and Oncology, University of Florence, viale G. B. Morgagni 50, 50134, Firenze</aff>
      <aff id="aff3"><label>3</label>Department of Human Pathology and Oncology, University of Florence, viale G.B. Morgagni 85, Firenze, 50134, Italy</aff>
      <pub-date pub-type="ppub">
        <month>08</month>
        <year>2001</year>
      </pub-date>
      <volume>85</volume>
      <issue>3</issue>
      <fpage>333</fpage>
      <lpage>336</lpage>
      <history>
        <date date-type="received">
          <day>15</day>
          <month>11</month>
          <year>2000</year>
        </date>
        <date date-type="rev-recd">
          <day>14</day>
          <month>03</month>
          <year>2001</year>
        </date>
        <date date-type="accepted">
          <day>02</day>
          <month>05</month>
          <year>2001</year>
        </date>
      </history>
      <copyright-statement>Copyright 2001, Cancer Research Campaign</copyright-statement>
      <copyright-year>2001</copyright-year>
      <permissions>
        <copyright-holder>Cancer Research Campaign</copyright-holder>
      </permissions>
      <abstract>
        <p>We report here a case of a patient affected by endometrial cancer and treated primarily with leuprolide, the surgical approach being unfeasible due to her compromised conditions. The therapy was continued for more than 6 years, and no progression of the disease was observed. During this period, some histological and immunohistochemical evaluations of the tumour (morphology, grading, proliferation and apoptotic index, E-cadherin expression) were performed. Furthermore, the expression of m-RNA for luteinizing-hormone releasing hormone (LHRH) receptors was determined. The results showed a discrepancy between some biological parameters of the tumour and its clinical characteristics. In fact, despite features suggestive of a progression of the cancer (such as the increase of both tumour grading and proliferating capacity (MIB-1), and a fall in the reparative process (appearance of mutated p53, reduced expression of both bcl-2 and c-erb-2) being detected, neither local invasion nor metastatic lesions were clinically observed. This discrepancy might be due to the maintenance of high levels of E-cadhezin. Moreover, since this tumour was shown to express mRNA for LHRH receptors, new evidence is provided about the favourable impact of LHRH analogue treatment in patients affected by endometrial cancer. &#xA9; 2001 Cancer Research Campaign <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.bjcancer.com">http://www.bjcancer.com</ext-link></p>
      </abstract>
      <kwd-group>
        <kwd>endometrial cancer</kwd>
        <kwd>LHRH analogues</kwd>
        <kwd>leuprolide</kwd>
      </kwd-group>
    </article-meta>
  </front>
</article>
</pmc-articleset>
